6 November 2025
Cancers | Highly Viewed Papers and Hot Topic Special Issues Published in the “Cancer Therapy” Section
You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.
Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.
Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.
Original Submission Date Received: .
We are delighted to share a collection of highly viewed papers in the “Cancer Therapy” Section that were published in Cancers (ISSN: 2072-6694) in the first half of 2025. In addition, some Special Issues on this topic are currently open for submission. The following is a list of articles and Special Issues that we believe may be of interest to you:
The list of relevant papers can be seen below:
“Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma”
by Navid Sobhani, Matteo Pittacolo, Alberto D’Angelo and Giovanni Marchegiani
Cancers 2025, 17(4), 704; https://doi.org/10.3390/cancers17040704
Available online: https://www.mdpi.com/2072-6694/17/4/704
“Advancing Cancer Treatment: A Review of Immune Checkpoint Inhibitors and Combination Strategies”
by Valencia Mc Neil and Seung Won Lee
Cancers 2025, 17(9), 1408; https://doi.org/10.3390/cancers17091408
Available online: https://www.mdpi.com/2072-6694/17/9/1408
“Ancestry-Specific DNA Damage Repair Gene Mutations and Prostate Cancer”
by Talaibek Borbiev, Kevin Babcock, Kayleigh Sinopole, Gregory T. Chesnut and Gyorgy Petrovics
Cancers 2025, 17(4), 682; https://doi.org/10.3390/cancers17040682
Available online: https://www.mdpi.com/2072-6694/17/4/682
“Triple-Negative Breast Cancer Progression and Drug Resistance in the Context of Epithelial–Mesenchymal Transition”
by Ewa Błaszczak, Paulina Miziak, Adrian Odrzywolski, Marzena Baran, Ewelina Gumbarewicz and Andrzej Stepulak
Cancers 2025, 17(2), 228; https://doi.org/10.3390/cancers17020228
Available online: https://www.mdpi.com/2072-6694/17/2/228
“Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics”
by Yan-You Liao, Chia-Luen Tsai and Hsiang-Po Huang
Cancers 2025, 17(3), 459; https://doi.org/10.3390/cancers17030459
Available online: https://www.mdpi.com/2072-6694/17/3/459
“Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies”
by Ayrton Bangolo, Behzad Amoozgar, Charlene Mansour, Lili Zhang, Sarvarinder Gill, Andrew Ip and Christina Cho
Cancers 2025, 17(2), 282; https://doi.org/10.3390/cancers17020282
Available online: https://www.mdpi.com/2072-6694/17/2/282
Special Issues:
|
“New Insights into Cancer Radiotherapy” |
“Advances in Lung Cancer Treatment Strategies” |
|
|
|
|
“Advances in the Treatment of Upper Gastrointestinal Cancer” |
“Unique Perspectives in Cancer Signaling (2nd Edition)” |
|
|
|
You can view and submit relevant papers to Cancers via the following link: https://www.mdpi.com/journal/cancers.
Cancers Editorial Office